Dr. Cynthia Lander, PhD: Founder, Chairman and Chief Executive Officer. Dr. Lander has been a Partner in Nascent Enterprises, LLC, a venture catalyst partnership commercializing medical inventions, with 24 companies created to date. Portfolio companies (including Moerae) have raised millions of dollars in private financing and experienced 12 exit transactions. Dr. Lander has overseen the development of Moerae Matrix, Inc. and spin-off VasoPrep Surgical, LLC as Founder, Chairman and CEO since Company inception. Via Cynapse Consulting, LLC, Dr. Lander has served as interim management and/or strategic consultant to numerous venture capital and development-stage biotechnology, medical device and diagnostics company clients, focusing on commercial opportunity assessment, corporate, product and market development strategy and operations, including such companies as Adamas Pharmaceuticals, Angelica Therapeutics, Crescendo Bioscience and Elizabeth Therapeutics. Cynapse Consulting clients have spanned early-stage start-ups through small- and large-cap pharmaceutical companies. Dr. Lander was Senior Vice President, Group Account Director at Saatchi & Saatchi/Publicis Group, with responsibility for business development and brand/marketing strategy for biopharmaceutical clients. She received her PhD in Neuroscience from Yale University (Neurogen Fellow), where she made discoveries that were subsequently out-licensed for use in research and drug development, and conducted post-doctoral research at Rockefeller University as a Revson Fellow. Dr. Lander is an inventor on numerous patents. She was a keyboard performance major at The Juilliard School and has a BS in Psychology from New York University.
Dr. Alyssa Panitch, PhD: Founding Scientist. Dr. Panitch is the Leslie A. Geddes Professor of Biomedical Engineering in the Weldon School of Biomedical Engineering and the Vice Provost for Faculty Affairs at Purdue University. In addition, she serves as the Director of Deliberate Innovation for Faculty in Life Sciences and Medical Technologies in the Burton D. Morgan Center for Entrepreneurship at Purdue. Dr. Panitch has been federally funded since 2002 including NIH, NSF, and DOD funding. She has over 75 publications in peer-reviewed journals and over 60 invited talks based on her work. She is on the editorial advisory board for Biomacromolecules and for Biomatter, is an associate editor for Cellular and Molecular Bioengineering, and is a past regular member of the Biomaterials and Biointerfaces Study Section. She was the founder and CSO of a start-up company, AzERx (Arizona Engineered Therapeutics). AzERx completed a Phase I and Phase II STTR that advanced the Company to acquisition by Orthologic, Inc in 2006 in a deal then valued at $7M (currently “Capstone Therapeutics”). Dr. Panitch is a founder and scientific advisory board member of Symic Biomedical, Inc. a venture-funded company commercializing a platform technology developed in the Panitch laboratory. She co-founded Moerae Matrix, Inc., on technology developed in her laboratory at Purdue University. Dr. Panitch received her BS from Smith College in biochemistry, BA and PhD from U Mass Amherst in chemical engineering and polymer science, and did post-doctoral work in biomedical engineering at the University of Zurich
Dr. Colleen Brophy, MD: Chief Scientific Officer. Dr. Brophy, tenured Professor at the Department of Vascular Surgery at Vanderbilt University, has been continuously funded by the NIH and the VAMC for over 15 years. She has over 100 publications in peer reviewed journals and has edited a textbook on Vascular Surgery. With Dr. Panitch, she was the founder and eventual CEO of the start-up company, AzERx. She served as a Commissioner for the State of Arizona (Arizona Biomedical Research Commission), Chair of the Surgical Research Committee for the American College of Surgeons and Chair of the Bioengineering Technology and Surgical Sciences (BTSS) study section for the NIH. Dr.Brophy received her BS in chemistry and molecular biology and MD at the University of Utah, was a surgical resident and post-doctoral fellow at Yale University, and a vascular fellow at Harvard University.
Dr. William Bradford, MD, PhD: Chief Medical Officer. Bill is an accomplished executive and scientist with 17 years’ experience in the biopharma industry in various executive, clinical development, and medical affairs roles, and over 20 years in clinical research. Most recently, Bill served as Senior Fellow and previously as SVP of Clinical Science and Biometrics at InterMune, where he was a member of the Executive Committee. He was the architect of the Esbriet clinical development program and responsible for many aspects of the successful development and regulatory approvals of Esbriet for the treatment of IPF. Bill also held leadership responsibilities for anti-infective and oncology clinical development programs, and was integral to the long-term value creation that culminated in the acquisition of InterMune by Roche in 2014. Prior to InterMune, Bill held clinical positions at IntraBiotics Pharmaceuticals and Genentech. He also practiced academic medicine in the Division of Infectious Diseases at the University of California, San Francisco, with a research focus on tuberculosis and HIV. Bill trained in internal medicine and infectious diseases at the University of California, San Francisco. He received a doctorate in epidemiology from the University of California, Berkeley, and a medical degree from the University of North Carolina, Chapel Hill, and is a graduate of Williams College. He serves on the Board of Directors of the Bluefield Project, a foundation focused on therapies for frontotemporal dementia.
Dalton Einhorn, MBA: Chief Operating Officer. Dalton Einhorn has more than 20 years of experience in biopharmaceutical start-ups, life sciences venture capital, pharmaceutical commercial operations and investment banking. Most recently he has had several entrepreneurial roles including as a co-founder of an early-stage oncology therapeutics company and as an advisor to several emergent medical device and biotherapeutics companies. Prior to that, he was a venture capital investor for Johnson & Johnson Development Corporation and Latterell Venture Partners, and was an investor in Genocea Biosciences, Astute Medical and PowerVision, Inc., and a board member of ViaCyte, Inc. Prior to his venture capital career, Mr. Einhorn held a number of branded products marketing and global new product commercialization roles at Roche, Daiichi-Sankyo and Novo Nordisk, and he has an extensive background in valuation, forecasting and business modeling, as well as business development. He began his career in the Mergers and Acquisitions group of CS First Boston (now Credit Suisse). Mr. Einhorn has a B.A. from Drew University and an MBA from Yale University.
Andrew D. Luber, Pharm.D.: VP Clinical Pharmacology. Dr. Luber is a clinical pharmacist/pharmacologist with over 20 years of experience in drug development and clinical research. As Executive Director of Research for both Pacific Oaks Medical Group and Tower ID Research in Los Angeles, CA, Dr. Luber was a clinical investigator in more than 70 clinical trials, including 4 Phase 1a/b studies. Dr. Luber has authored textbook chapters and numerous articles in peer-reviewed journals and on-line resources in the area of HIV Pharmacology and Pharmacokinetics and helped to develop the American Academy of HIV Medicine’s (AAHIVM) Self-Directed Study Guide by authoring the Pharmacology and Pharmacokinetic sections. In addition, he was a core faculty member that worked to develop The Viral Hepatitis Mid-Level Provider Certification Program for the American Association for Study of Liver Diseases (AASLD). Dr. Luber has worked with many different pharmaceutical companies as an investigator, speakers’ bureau, steering committee and advisory board member, as well as serving as a clinical consultant to both large and early stage pharmaceutical companies. Dr Luber received his B.S. Pharm and Pharm.D. from Temple University School of Pharmacy, Philadelphia PA. He completed his residency in both pharmacy practice and infectious diseases, as well his research fellowship in infectious diseases pharmacotherapy, at the University of California, San Francisco, School of Pharmacy, San Francisco, California.
Caryn Peterson: Executive Vice President, Regulatory and Development Operations. In 2010, Ms. Peterson joined Moerae Matrix, Inc. as Vice President of Regulatory Affairs to oversee development of the Company’s drug portfolio from IND-enabling studies into the clinic. Ms. Peterson has over 30 years of pharmaceutical industry experience, including research and development, regulatory affairs, and operations. She has extensive experience in the area of global regulatory affairs for small molecules, peptide therapeutics, and biologics. Ms. Peterson co-founded the consulting firm DSC Associates (“DSC”) in 2004, to provide consulting services to the pharmaceutical, biotechnology and medical device industries, focusing on preclinical, regulatory and clinical strategies designed to streamline product development. Prior to founding DSC, she served on FeRx Incorporated’s Executive Management Team as Vice President of Regulatory Affairs responsible for development and subsequent execution of the global nonclinical, clinical and regulatory strategies for the lead compound and platform technology. Prior to FeRx, Ms. Peterson held senior managerial positions at Amylin Pharmaceuticals in Pharmaceutical Development and Regulatory Affairs. Ms. Peterson was involved in the early discovery program and subsequent clinical development of pramlintide (Symlin®), a peptide drug for Type 1 diabetes.
Anthony Dimun, CPA: Co-Founder. Tony has a 30 year history of highly successful operational, business development and financial experience in the healthcare market. Since 2001, Tony has served as Chairman of Nascent Enterprises LLC, a group of medical industry entrepreneurs focused on successful commercialization of promising medical inventions. From 1987 to 2001, Tony served as Executive Vice President and Chief Financial Officers of Vital Signs Inc., a publicly-held anesthesia, respiratory and sleep apnea medical device business, providing growth strategies to enhance the Company’s value through highly focused bolt on acquisitions. Vital Signs was sold to GE Medical in 2008 for $1B. During the past 20 years he has been an investor and mentor to several emerging growth medical enterprises that have matured to commercial status and became publicly traded companies, acting either as the Founder or participating in the founding of 12 medical device companies. Of these four became public companies and twelve were sold. Tony have been a director of several public companies, including Vital Signs, Inc., Bionix Implants,Inc., Colorado Medtech Inc, Photomedix, Inc., SSI Surgical and numerous privately held companies in the healthcare field. He has also served as advisor to several universities, such as the University of Pennsylvania and the Biomaterials Institute of Rutgers University. Prior to 1990, Mr. Dimun held positions as a Certified Public Accountant with national accounting firms and severed as the Senior Vice President for an international merchant banking firm specializing in mergers and acquisitions.
Neal Murakami, CPA: Vice President and Controller. Mr. Murakami joined Moerae Matrix in 2010 where he directs accounting and finance functions for the company. Mr. Murakami has over 25 years of accounting, finance and audit experience within the life sciences and technology industries ranging from established companies to start-up organizations. Prior to joining Moerae Matrix, Mr. Murakami led the accounting departments of Tethys Biosciences and Guava Technologies. Mr. Murakami holds a B.S. in Business Administration (Accounting emphasis) from California State University, Hayward.